XML 49 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue (Tables)
12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
Our disaggregated revenues were as follows (in thousands):
Year Ended December 31,
202420232022
Royalties$570,991 $447,865 $360,475 
Product sales, net
Proprietary product sales
166,620 130,834 72,849 
Bulk rHuPH20 sales
86,334 115,442 82,084 
Device partnered product sales
50,538 54,578 36,097 
Total product sales, net303,492 300,854 191,030 
Revenues under collaborative agreements
Upfront license and target nomination fees
27,000 2,000 30,000 
Event-based development and regulatory milestones and other fees
72,500 69,000 59,000 
Sales-based milestones
30,000 — 10,000 
Device licensing and development revenue
11,341 9,534 9,611 
Total revenues under collaborative agreements140,841 80,534 108,611 
Total revenues
$1,015,324 $829,253 $660,116 
Schedule of Accounts Receivable, Other Contract Assets and Contract Liabilities
Accounts receivable, net, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands):
December 31, 2024December 31, 2023
Accounts receivable, net$288,204 $233,254 
Other contract assets20,251 956 
Deferred revenues10,343 4,048